Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 6/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566953 | 0.91 | P2RX7 (0.44) | P2RX7ABCB11PDE2ATHRB | |
| SCHEMBL5564868 | 0.88 | P2RX7 (0.45) | P2RX7ABCB11PDE2ATHRBCCR1 | |
| SCHEMBL5566710 | 0.84 | P2RX7 (0.41) | P2RX7ABCB11PDE2ATHRB | |
| SCHEMBL5566088 | 0.84 | P2RX7 (0.46) | P2RX7ABCB11PDE2ATHRB | |
| SCHEMBL6478617 | 0.79 | MEN1 (0.47) | P2RX7ABCB11THRB | |
| SCHEMBL10673166 | 0.79 | P2RX7 (0.42) | P2RX7ABCB11PDE2ATHRB | |
| SCHEMBL5567074 | 0.77 | THRB (0.39) | P2RX7ABCB11THRB | |
| SCHEMBL5566129 | 0.77 | P2RX7 (0.46) | P2RX7ABCB11THRB | |
| SCHEMBL5560395 | 0.76 | MEN1 (0.43) | P2RX7ABCB11PDE2ATHRB | |
| SCHEMBL5561092 | 0.75 | P2RX7 (0.42) | P2RX7ABCB11THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090495-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | LACRAMPE JEAN FERNAND ARMAND (FR) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090495-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | CXCR5, HCAR3, IL6ST | P2RX7 274/4885ABCB11 2936/4885PDE2A 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.